Estrogen taken after menopause has had a complicated medical history.
Once widely prescribed, hormone therapy later became controversial after research raised concerns about dementia, cancer and heart problems.
Now a Stanford Medicine study suggests that one particular form of treatment may tell a different story. Women who used estrogen alone showed fewer physical signs of Alzheimer’s disease in their brains after death and were less likely to have been diagnosed with dementia while alive.
The distinction between estrogen-only therapy and other hormone treatments is crucial. Estrogen alone is generally prescribed to women who no longer have a uterus, most often because they have undergone a hysterectomy.
Women with a uterus normally receive another hormone, usually a form of progesterone, along with estrogen. The additional hormone protects the uterine lining from changes that could otherwise increase cancer risk.
The new research does not show the same benefit for every form of menopausal hormone therapy. Instead, its clearest conclusions concern women who reported using estrogen-only treatment.
Scientists have good reason to investigate hormones and Alzheimer’s disease. Women account for roughly two-thirds of Alzheimer’s patients, and estrogen affects many parts of the body, including the brain.
Alzheimer’s gradually damages nerve cells involved in memory, reasoning and everyday function. The disease is associated with abnormal amyloid plaques outside brain cells and tangles made from the protein tau inside them.
Clinical dementia diagnoses are useful but imperfect because many conditions can cause memory problems. Stroke, other forms of dementia, medicines, depression and even temporary illness can affect thinking, particularly in older adults.
For this reason, Stanford researchers wanted to examine the brain itself. Senior author Hadi Hosseini and colleagues used autopsy information to measure the physical hallmarks associated with Alzheimer’s disease.
The scientists searched two large databases containing information from 21,462 people. They identified deceased women whose brains had been examined after death and compared their history of menopausal hormone therapy with the amount of Alzheimer’s-related damage found at autopsy.
The key comparison involved 258 women who had used estrogen-only therapy and approximately 2,701 women who reported no menopausal hormone therapy. Researchers assessed amyloid plaques, tau tangles and the density of amyloid deposits.
The pattern favored estrogen-only users. Their brains showed significantly fewer Alzheimer’s-related changes, and statistical analysis indicated about 35% lower odds of Alzheimer’s pathology.
The researchers did not rely on autopsy evidence alone. They also examined information collected while the women were alive, including dementia diagnoses, memory tests and measures of independent functioning.
Estrogen-only users had 39% lower odds of having received a clinical diagnosis of dementia. They also tended to perform better on tests of memory and their ability to manage daily life.
These results remained after the team accounted for several factors known to affect Alzheimer’s risk. Those factors included age, high blood pressure, education, race and the APOE4 gene variant, one of the strongest known genetic risk factors for late-life Alzheimer’s disease.
The finding is particularly interesting because hormone therapy has been surrounded by conflicting evidence. Earlier observational studies sometimes suggested that estrogen might protect the brain, while later trials created serious doubts.
One of the most influential was the Women’s Health Initiative Memory Study, reported in 2003. It found an increased dementia risk among older women receiving estrogen together with progestin, particularly when therapy was started later in life.
Those results had a major impact on public attitudes toward menopausal hormones. Use of the therapy fell sharply, and warnings about possible health risks influenced medical practice for years.
But researchers have increasingly questioned whether results from one type of hormone treatment and one group of women should be applied to everyone. Starting hormones close to menopause may produce different effects from starting them much later, and estrogen alone may behave differently from estrogen combined with progestin.
The Stanford researchers could not settle the question for combined therapy. Too few women using estrogen-plus-progestin had suitable autopsy information, so the study did not have enough evidence to determine whether that treatment raises, lowers or leaves Alzheimer’s risk unchanged.
The study also excluded topical estrogen users. As a result, the findings cannot be automatically applied to estrogen delivered through patches, gels or other skin-based treatments.
The women studied were relatively old, with an average age around 70, and many had undergone hysterectomies. The researchers noted that newer medical thinking often favors beginning hormone therapy during or relatively soon after menopause when treatment is appropriate.
The study was published August 12, 2026, in Neurology and was led by Stanford Medicine investigators including Hadi Hosseini and Jennifer Bruno. According to the researchers, it is the first analysis of menopausal hormone therapy to include substantial numbers of postmortem brains assessed directly for Alzheimer’s pathology.
The research is valuable because autopsy evidence is less dependent on subjective judgments about memory decline. Finding a similar pattern in brain tissue, dementia diagnoses and cognitive testing also makes the overall result more convincing.
Yet the study still cannot establish cause and effect. It did not randomly assign women to estrogen or no treatment, so unknown differences between users and nonusers could partly explain the apparent protection.
That limitation is important for anyone wondering whether estrogen should be taken to prevent dementia. The results are not a recommendation to start hormone therapy solely for brain protection, and estrogen treatment can carry risks that depend on a woman’s age and medical history.
The strongest conclusion is narrower but still important. Estrogen-only therapy does not appear to fit neatly with the old assumption that menopausal hormones simply increase dementia risk, and it may be associated with a meaningful reduction in Alzheimer’s-related changes for some women.
Future research should test different formulations, doses, starting ages and treatment durations separately. If clinical trials eventually confirm a protective effect, doctors may be able to make hormone decisions based not only on menopausal symptoms but also on a much clearer understanding of long-term brain health.
Source: Stanford Medicine.
